We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The lawsuit alleges that the approval of Ruzurgi, a rival drug from privately held Jacobus Pharma, violated provisions of FDA regulations and Catalyst’s rights to exclusivity for its drug, Firdapse